---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-26-000042"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:36:50.241703+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Biogen Q1 revenue $2.5B, EPS beat; proposes Apellis acquisition, updates FY2026 guidance

## Summary
- Q1 rev $2.5B (+2% YoY); GAAP EPS $2.15 (+31%); Non-GAAP EPS $3.57 (+18%).
- Growth products: LEQEMBI $168M (+74%), SKYCLARYS $151M (+22%), ZURZUVAE $55M (+100%), VUMERITY $179M (+29%), QALSODY $33M (+110%).
- Proposed Apellis acquisition expected to close Q2 2026, accretive in 2027; Biogen to update guidance post-close.
- FY2026 Non-GAAP EPS guidance $14.25-$15.25 (ex-Apellis); total revenue seen declining mid-single digit % vs 2025.
- Pipeline: litifilimab Phase 2 CLE positive; SPINRAZA High Dose Regimen FDA approved; felzartamab rights in Greater China acquired.

## SEC filing metadata
- accession: 0000875045-26-000042
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/0000875045-26-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/biib-20260429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-26-000042
- JSON: https://secwatch.observer/filing/0000875045-26-000042.json
- Plain text: https://secwatch.observer/filing/0000875045-26-000042.txt

## Key facts
- Earnings Releases
  BIOGEN INC. reported the first quarter ended March 31, 2026 results: revenue $2,478, EPS GAAP diluted EPS $2.15; Non-GAAP diluted EPS $3.57. Guidance raised.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $2,478
  - EPS: GAAP diluted EPS $2.15; Non-GAAP diluted EPS $3.57
  - Guidance: raised
  - Result: reported results
  source text: and reported important positive new data that reinforce our confidence in the late‐stage pipeline." Financial Highlights Q1 '26 Q1 '25 △ r (CC * ) Total Revenue (in millions) $2,478 $2,431 2% (2)% GAAP diluted EPS $2.15 $1.64 31% N/A Non-GAAP diluted EPS $3.57 $3.02 18% N/A Note: Percent changes represented as favorable/(unfavorable) versus the prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/0000875045-26-000042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.